People: MAP Pharmaceuticals, Inc. (MAPP.O)

MAPP.O on Consolidated Issue listed on NASDAQ Global Market

14.98USD
9 Feb 2010
Price Change (% chg)

$-0.05 (-0.33%)
Prev Close
$15.03
Open
$15.19
Day's High
$15.21
Day's Low
$14.89
Volume
110,074
Avg. Vol
256,534
52-wk High
$16.80
52-wk Low
$1.57

view people for:

Summary

Name Age Since Current Position
Elms, Steven 45 2004 Chairman of the Board
Nelson, Timothy 45 2005 President, Chief Executive Officer, Director
Chai, Christopher 42 2006 Chief Financial Officer
Gianakakos, Anastasios 36 2006 Senior Vice President - Corporate and Business Development
Kellerman, Donald 54 2008 Senior Vice President - Clinical Development and Medical Affairs
Petro, Alan 2009 Vice President - Manufacturing and Technical Operations
Friedman, Charlene 51 2007 Vice President, General Counsel, Secretary
Rosa, Marco 48 2008 Vice President - Human Resources
Cohen, Alan 2008 Vice President - Clinical Development and Medical Affairs, Pulmonary
Armer, Thomas 55 Chief Scientific Officer, Director
Freund, John 55 2004 Director
Goldfischer, Carl 50 2004 Director
Henwood, Gerri 56 2004 Director
Kelley, Bernard 68 2007 Director
McPherron, Matthew 44 2006 Director
Wolff, H. Ward 60 2008 Director
Ward, Scott 49 2008 Director
» Insider Trading

Biographies

Name Description
Elms, Steven Mr. Steven A. Elms has served as Chairman of Board of Directors since June 2004. Since 2000, Mr. Elms has served as a Managing Director of the Perseus-Soros BioPharmaceutical Fund L.P., a private equity firm, and since 2005, has served as a Managing Director of Aisling Capital LLC, a private equity firm. From 1995 to 2000, Mr. Elms served as a Principal at the Life Sciences Investment Banking Group of Chase H&Q, formerly known as Hambrecht & Quist. Mr. Elms is a member of the board of directors of a number of private companies. Mr. Elms received an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in human biology from Stanford University.
Nelson, Timothy Mr. Timothy S. Nelson is President, Chief Executive Officer, Director of MAP Pharmaceuticals Inc. He has served as the company's President and Chief Executive Officer since April 2005. From 1998 to 2005, Mr. Nelson served as Senior Vice President of Commercial and Business Development at DURECT Corporation, a pharmaceutical company. From 1992 to 1998, Mr. Nelson held various senior management positions with Medtronic, Inc., a medical device company, including Business Director of the Neurological Division for Europe, the Middle East and Africa from 1996 to 1998. Mr. Nelson received an M.M. from the Kellogg School of Management at Northwestern University and a B.S. in chemical engineering from the University of Minnesota.
Chai, Christopher Mr. Christopher Y. Chai has served as Chief Financial Officer since September 2006. From 1998 to 2006, Mr. Chai was employed by CV Therapeutics, Inc., a biopharmaceutical company, where he held various management positions, including Vice President, Treasury and Investor Relations. From 1988 to 1998, Mr. Chai worked at J.P. Morgan & Co. Incorporated, most recently as a healthcare investment banker. Mr. Chai received a B.S. in operations research and industrial engineering from Cornell University.
Gianakakos, Anastasios Mr. Anastasios E. Gianakakos has served as Senior Vice President of Corporate and Business Development since September 2006. From 2001 to 2006, Mr. Gianakakos held a variety of leadership positions at Codexis, Inc., a biotechnology company, including Senior Vice President of Business Development and head of Codexis’s Pharmaceuticals Business Unit. From 1998 to 2001, Mr. Gianakakos was Director of Business Development at Maxygen, Inc., a biopharmaceutical company. Mr. Gianakakos received an M.B.A. from Harvard Business School, an M.S. in biotechnology from Northwestern University, and a B.S. in chemical engineering and a B.S. in economics from the Massachusetts Institute of Technology.
Kellerman, Donald Dr. Kellerman is Senior Vice President - Clinical Development and Medical Affairs of MAP Pharmaceuticals Inc since July 2008. From 1999 to 2008, Dr. Kellerman held leadership positions at Inspire Pharmaceuticals, Inc., a pharmaceuticals company, as Senior Vice President, Development since May 2000, and as Vice President, Development from July 1999 to May 2000. Previously, Dr. Kellerman was employed in senior clinical positions at Glaxo Wellcome and Sepracor, Inc. Dr. Kellerman holds Doctor of Pharmacy and B.S. degrees from the University of Minnesota.
Petro, Alan Mr. Alan Petro has been appointed as Vice President - Manufacturing and Technical Operations of MAP Pharmaceuticals, Inc. Mr. Petro brings to the company more than 25 years of product/process development and manufacturing operations experience within the healthcare industry. Most recently, Mr. Petro was Vice President of Supply Chain Management for Carl Zeiss Meditec, Inc. where he was responsible for both internal manufacturing and external vendor supply, as well as procurement. Mr. Petro also implemented lean manufacturing methods and developed a strategic sourcing business model. Previously, he held positions with senior and executive level responsibilities in product engineering, supply chain, manufacturing and regulatory affairs at Siemens Medical Solutions and General Electric Medical Systems. Mr. Petro holds a Bachelor of Science degree in Materials and Metallurgical Engineering from the University of Michigan and a Masters of Business Administration from Marylhurst University.
Friedman, Charlene Ms. Charlene A. Friedman has served as Vice President, General Counsel and Secretary since July 2007. From 2005 to 2007, Ms. Friedman served as Vice President, General Counsel and Secretary of VNUS Medical Technologies, Inc., a medical device company. From October 2004 to October 2005, Ms. Friedman provided limited consulting services to R2 Technology, Inc., a medical device company, and from October 2002 to September 2004, served as their Vice President, General Counsel and Secretary. From 2000 to 2002, Ms. Friedman served as Vice President, General Counsel and Secretary at Aviron, a biopharmaceutical company. From 1996 to 1999, Ms. Friedman served as Vice President, Legal and Regulatory Affairs, General Counsel and Assistant Secretary at Collagen Aesthetics, Inc., a medical device company. Prior to joining Collagen, Ms. Friedman was in private practice for over 10 years. She is a member of the California and Massachusetts state bars and holds a J.D. from the Northeastern University School of Law and a B.A. in Ancient Greek and Latin from Tufts University.
Rosa, Marco Marco F. Rosa is Vice President of Human Resources of the Company. Mr. Rosa brings over 20 years of human resources experience to the Company. Most recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. as Vice President of Worldwide Human Resources, a position he had held since May of 2002. He was an integral part of the senior management team overseeing the company's growth and the commercial launch of several ophthalmology and surgical microscopy devices. Prior to Carl Zeiss, Mr. Rosa served as Vice President, Human Resources at COR Therapeutics, Inc., building the development and commercial organizations and launching Integrilin(R) in the cardiovascular angioplasty market. Before joining COR, Mr. Rosa held senior human resources and key administrative management positions with ReplayTV, Inc., Genelabs Technologies, Inc., and Sony Electronics Inc. Prior to 1990, Mr. Rosa held similar management positions with the General Electric Company where he started his career in human resources. In addition to his extensive human resources experience, Mr. Rosa served as a Captain in the BioMedical Corps of the United States Air Force. Mr. Rosa received his B.A. degree in Psychology from St. Michael's College and his M.A. degree in Counseling Psychology from New York University.
Cohen, Alan Alan H. Cohen, M.D., FAAP, FCCP, has been appointed as Vice President - Clinical Development and Medical Affairs, Pulmonary of MAP Pharmaceuticals, Inc. In his new role, Dr. Cohen will oversee development and execution of MAP Pharmaceuticals' pediatric asthma clinical program, including Phase 3 clinical trials for Unit Dose Budesonide (UDB). Dr. Cohen will direct the initiation, execution and evaluation of clinical trials and lead clinical interactions with global regulatory authorities. Dr. Cohen brings more than 20 years of therapeutic, clinical and medical experience, with specific expertise in the field of pediatric pulmonology -- including asthma, chronic obstructive pulmonary disease and cystic fibrosis. Most recently, Dr. Cohen was Chief Medical Officer and Vice President of Global Medical Affairs, Safety & Pharmacovigilance at Jazz Pharmaceuticals, Inc., where he was actively involved in all levels of clinical research, from pre-clinical work through Phase 4 development. He built the department of medical affairs, overseeing all aspects of his team, including investigator initiated trials, medical education, field-based medical affairs, advisory boards as well as safety and pharmacovigilance. Prior to his tenure at Jazz Pharmaceuticals, Dr. Cohen was Senior Director of Medical Affairs at MedImmune, Inc., where he played a central role in brand support for their respiratory products, including Synagis(R), FluMist(R) and RespiGam(TM). He has also worked in private practice as a pediatric pulmonologist, affiliated with Emory University, Morehouse School of Medicine and Scottish Rite Children's Medical Center, in Atlanta, GA. Dr. Cohen received his Bachelor of Science and Bachelor of Arts from the University of Rochester and his medical degree from New York Medical College. He completed his residency and fellowship training in Pediatrics and Pediatric Pulmonology, respectively, at the University of Colorado School of Medicine and the National Jewish Center for Immunology and Respiratory Disease.
Armer, Thomas Mr. Thomas A. Armer has served as Chief Scientific Officer and as a member of Board of Directors since inception and served as President and Chief Executive Officer from inception to April 2005. From 1998 to 2003, Dr. Armer served as Vice President of Pulmonary Delivery Systems and later as Chief Scientific Officer at Sheffield Pharmaceuticals, Inc., a pharmaceutical company. Sheffield Pharmaceuticals filed for Chapter 7 bankruptcy in June 2003. From 1989 to 1998, Dr. Armer held a series of senior management and product development positions at the Novon Products Group, a division of Warner-Lambert, and Aeroquip Vickers Corporation. Dr. Armer received a Ph.D. in chemical engineering from Tulane University.
Freund, John Mr. John G. Freund has served as a Member of Board of Directors since August 2004. Since 1997, Dr. Freund has been a Managing Director of Skyline Ventures, a venture capital firm. From 1995 to 1997, Dr. Freund served as a Managing Director in the private equity group at Chancellor Capital Management, Inc., an investment firm. In 1995, Dr. Freund co-founded Intuitive Surgical Inc., a medical device company, and served as a Director until 2000. From 1988 to 1994, he held various positions at Acuson Corporation, including Executive Vice President. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., Inc., where he was the co-founder of the Healthcare Group in the Corporate Finance Department and later was the original healthcare partner at Morgan Stanley Venture Partners. Dr. Freund serves on the boards of directors of Hansen Medical, Inc., a medical device company, XenoPort, Inc., a biopharmaceutical company, Sirtris Pharmaceuticals, Inc., a biopharmaceutical company, The New Economy Fund, The SMALLCAP World Fund and a number of private companies. Dr. Freund received an M.B.A. from Harvard Business School, where he graduated with high distinction and was a Baker Scholar, an M.D. from Harvard Medical School and a B.A. from Harvard College.
Goldfischer, Carl Mr. Carl S. Goldfischer has served as a Member of Board of Directors since August 2004. Since 2001, Dr. Goldfischer has been employed by Bay City Capital LLC, a venture capital firm, where he is currently an Investment Partner and Managing Director and serves as a member of its board of directors and executive committee. From 1996 to 2000, Dr. Goldfischer served as the Chief Financial Officer of ImClone Systems Incorporated, a pharmaceutical company. Dr. Goldfischer is a member of the board of directors of EnteroMedics, Inc., a biomedical device company, and Poniard Pharmaceuticals, Inc., a biopharmaceutical company, and a number of private companies. He received an M.D. from the Albert Einstein College of Medicine and a B.A. from Sarah Lawrence College.
Henwood, Gerri Ms. Gerri A. Henwood has served as a Member of Board of Directors since June 2004. Ms. Henwood is currently the President of an independent consulting firm, Malvern Consulting Group. From 1999 to July 2006, Ms. Henwood was President, Chief Executive Officer, and until May 2005, Chairman of the Board of Auxilium Pharmaceuticals, Inc., a pharmaceutical company. From 1985 to 1999, Ms. Henwood served as President and Chief Executive Officer of IBAH, Inc., a publicly traded contract research company, originally named Bio-Pharm Clinical Services, Inc., a company which she founded. Ms. Henwood is a member of the board of directors of Alkermes, Inc. a pharmaceutical company. She received a B.S. from Neuman College.
Kelley, Bernard Mr. Bernard J. Kelley has served as a Member of Board of Directors since May 2007. From 1993 to 2002, Mr. Kelley was the President of the Merck Manufacturing Division, a division of Merck & Co., Inc., and he served as a member of the Merck Management Committee from 1995 to 2002. Since 2003, Mr. Kelley has served as a member of the board of directors of Aegis Analytical Corporation, a private enterprise software company. Mr. Kelley currently serves on the board of directors of Codexis, Inc., a private biotechnology company. Mr. Kelley received a B.S. in engineering from the U.S. Naval Academy.
McPherron, Matthew Mr. Matthew V. McPherron has served as a Member of Board of Directors since January 2006. Since 1998, Mr. McPherron has been employed by Brookside Capital, LLC, an investment fund, where he is currently a Managing Director. From 1997 to 1998, Mr. McPherron served as the President and Chief Operating Officer for U.S. Carelink, Inc., a clinical information company. Mr. McPherron received an M.B.A. from Harvard Business School and a B.S. from the University of Kansas.
Wolff, H. Ward Mr. H. Ward Wolff has served as a Member of Board of Directors since March 2008. Since 2007, Mr. Wolff has been employed by Sangamo BioSciences, Inc. as Executive Vice President and Chief Financial Officer. Mr. Wolff was formerly with Nuvelo, Inc., where he served as Senior Vice President, Finance and Chief Financial Officer until its restructuring in August 2007. Prior to joining Nuvelo, he was Senior Vice President, Finance and Chief Financial Officer of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and CFO of DoubleTwist, Inc., a life sciences company. Mr. Wolff is also a member of the board of directors of a private pharmaceutical company. Mr. Wolff received a B.A. degree in Economics from the University of California at Berkeley and an M.B.A. from Harvard Business School.
Ward, Scott Mr. Scott R. Ward has been appointed to the board of Directors of MAP Pharmaceuticals, Inc. September 2008. Mr. Ward has been employed by Medtronic, Inc., a medical device company, since 1981 and has served as Senior Vice President and President, Medtronic CardioVascular since May 2007. Previously, Mr. Ward served as Senior Vice President and President of Medtronic Neurological and Diabetes, Vice President and General Manager of the Medtronic Drug Delivery Business and President of Medtronic Neurological. Mr. Ward received a B.S. in Genetics and Cell Biology in 1981, and an M.S. in Toxicology in 1983, both from the University of Minnesota.

Insider Trading

Name Shares Traded Price
GIANAKAKOS ANASTASIOS 8,250 $0.74
GIANAKAKOS ANASTASIOS 8,250 $14.95
GIANAKAKOS ANASTASIOS 5,000 $0.74
GIANAKAKOS ANASTASIOS 5,000 $14.95
NELSON TIMOTHY S 20,000 $12.17
NELSON TIMOTHY S 20,000 $0.64
GIANAKAKOS ANASTASIOS 4,500 $0.74
GIANAKAKOS ANASTASIOS 4,500 $9.92
ARMER THOMAS A 10,000 $3.36
ARMER THOMAS A 10,000 $9.54
GIANAKAKOS ANASTASIOS 5,674 $2.70
NELSON TIMOTHY S 1,779 $2.70
CHAI CHRISTOPHER Y 1,730 $2.70
HENWOOD GERALDINE A 16,250 $8.77
HENWOOD GERALDINE A 16,250 $0.64
CHAI CHRISTOPHER Y 10,000 $8.07
GIANAKAKOS ANASTASIOS 4,500 $0.74
CHAI CHRISTOPHER Y 10,000 $0.74
GIANAKAKOS ANASTASIOS 4,500 $8.06
GIANAKAKOS ANASTASIOS 4,500 $0.74
CHAI CHRISTOPHER Y 10,000 $0.74
GIANAKAKOS ANASTASIOS 4,500 $10.20
CHAI CHRISTOPHER Y 10,000 $10.26
GIANAKAKOS ANASTASIOS 4,500 $10.03
GIANAKAKOS ANASTASIOS 4,500 $0.74
» Full list on Insider Trading
view people for: